I get a message the abstract is missing, but it IS here!!!!! Background: Chimeric Antigen Receptor (CAR)-NK/T-cells offer a new approach in immune therapy of haematological cancers. NK/T-cells bridge innate and adaptive immunity with strong anti-cancer effects. Unlike allogeneic CAR-T-cells, CAR-NK/T-cells do not require TCR genetic deletion to prevent major MHC recognition, have a lower risk of graft-versus-host disease (GvHD), and can be used universally. Summary: Pre-clinical studies report CAR-NK/T-cells effectively target antigens such as CD19 and BCMA in B-cell lymphomas and plasma cell myeloma (PCM). Compared with CAR-T-cells, CAR-NK/T-cells have faster immune responses, more cytotoxicity and better safety. Recent innovations increase efficacy of CAR-NK/T-cell therapies. Early clinical trials report promising safety and efficacy. Although still in the early phases of development advances in NK/T-cell therapy are overcoming prior challenges. Key Messages: CAR-NK/T-cells may prove a safer, more flexible form of cell therapy of haematological cancers.
Noorafrooz et al. (2025) studied this question.